2024
Trends and regional differences for fertility preservation procedures in women with breast cancer
Turan V, Bedoschi G, Lee D, Barbosa C, de Oliveira R, Sacinti K, Sonmezer M, Lambertini M, Massarotti C, Schaub A, Wang E, Gayete-Lafuente S, Dunlop C, Anderson R, Bang H, Oktay K. Trends and regional differences for fertility preservation procedures in women with breast cancer. Clinical Breast Cancer 2024 PMID: 39428290, DOI: 10.1016/j.clbc.2024.09.011.Peer-Reviewed Original ResearchWomen of reproductive ageFertility preservationBreast cancerTissue cryopreservationYoung womenReproductive ageOvarian tissue cryopreservationFertility preservation methodsNormal ovarian functionOvarian stimulation cyclesFertility preservation proceduresFertility preservation practicesDiagnosed breast cancerOocyte cryopreservationOvarian stimulationTertiary centerMulticenter studyOvarian functionStimulated cyclesParticipating centersRegional time trendsBreastCancerPreservation proceduresChemotherapyUtility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers
Erden M, Gayete-Lafuente S, Vural N, Oktay K. Utility and Outcomes of Ovarian Tissue Cryopreservation and Transplantation for Gynecologic Cancers. Obstetrics And Gynecology 2024, 144: 481-492. PMID: 39173181, PMCID: PMC11499045, DOI: 10.1097/aog.0000000000005708.Peer-Reviewed Original ResearchCryopreserved ovarian tissue transplantationOvarian tissue cryopreservationOvarian tissue transplantationTissue cryopreservationAutologous transplantationGynecologic cancerTissue transplantationOutcome of autologous transplantationPreserving ovarian functionCochrane Library databasesOvarian endocrine functionPooled-effect estimatesSystematic reviewRisk-of-bias assessmentOvarian stimulationHematologic malignanciesLonger-term outcomesFertility preservationOvarian functionBreast cancerLibrary databasesTransplantationGraft longevityCancerEndocrine function
2022
PRESENCE OF BRCA MUTATIONS AND A PRE-CHEMOTHERAPY AMH LEVEL OF < 2ng/ML STRONGLY PREDICT RISK OF AMENORRHEA IN WOMEN WITH BREAST CANCER
Oktay K, Turan V, Bedoschi G, Goldfarb S, Bang H. PRESENCE OF BRCA MUTATIONS AND A PRE-CHEMOTHERAPY AMH LEVEL OF < 2ng/ML STRONGLY PREDICT RISK OF AMENORRHEA IN WOMEN WITH BREAST CANCER. Fertility And Sterility 2022, 118: e231. DOI: 10.1016/j.fertnstert.2022.08.652.Peer-Reviewed Original ResearchFertility Preservation in Breast Cancer Patients
Marin L, Turan V, Oktay K. Fertility Preservation in Breast Cancer Patients. 2022, 185-198. DOI: 10.1007/978-3-030-47767-7_14.Peer-Reviewed Original ResearchFertility preservation issuesBreast cancerGonadotropin-releasing hormone agonistNovel chemotherapy regimensSafety of pregnancyFertility preservation techniquesBreast cancer survivorsBreast cancer patientsBreast cancer survivalPremature ovarian insufficiencyBreast cancer treatmentChemotherapy regimensOvarian suppressionPremenopausal womenOvarian reserveHormone agonistCancer survivorsCommon malignancyFertility preservationOvarian functionCancer patientsCancer survivalBRCA mutationsSexual dysfunctionFertility risks
2021
Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data
Turan V, Lambertini M, Lee D, Wang E, Clatot F, Karlan B, Demeestere I, Bang H, Oktay K. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. Journal Of Clinical Oncology 2021, 39: 2016-2024. PMID: 33891474, PMCID: PMC8260903, DOI: 10.1200/jco.20.02880.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataSerum AMH levelsDiminished ovarian reservePatient-level dataAMH levelsOvarian reservePathogenic variantsGermline BRCA pathogenic variantLow serum AMH levelsAnti-Müllerian hormone levelsOral contraceptive pill useLower AMH levelsDecreased ovarian reserveBody mass indexContraceptive pill useBRCA pathogenic variantsEvaluable womenMass indexMean ageHormone levelsBreast cancerAffected womenPill useMeta-AnalysisYoung women
2020
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
Goldfarb S, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, Bang H, Patil S, Dickler M, Oktay K. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Research And Treatment 2020, 185: 165-173. PMID: 32930927, PMCID: PMC7877450, DOI: 10.1007/s10549-020-05933-7.Peer-Reviewed Original ResearchConceptsAnti-Mullerian hormoneOvarian reserveAdjuvant chemotherapyBreast cancerAMH levelsChemotherapy regimensCompletion of ACSerum AMH levelsAdjuvant tamoxifenAMH recoveryChemotherapy groupPrimary diagnosisBaseline ageMethodsOne hundredAMH assessmentRegimensChemotherapyYoung womenTamoxifenSignificant recoveryCancerMixed effects modelsMonthsTreatment effectsWomenIMPACT OF ADJUVANT CHEMOTHERAPY OR TAMOXIFEN ALONE ON THE OVARIAN RESERVE OF YOUNG WOMEN WITH BREAST CANCER: A PROSPECTIVE LONGITUDINAL STUDY
Oktay K, Turan V, Bedoschi G, Taylan E, Bang H, Dickler M, Goldfarb S. IMPACT OF ADJUVANT CHEMOTHERAPY OR TAMOXIFEN ALONE ON THE OVARIAN RESERVE OF YOUNG WOMEN WITH BREAST CANCER: A PROSPECTIVE LONGITUDINAL STUDY. Fertility And Sterility 2020, 114: e531-e532. DOI: 10.1016/j.fertnstert.2020.09.051.Peer-Reviewed Original ResearchImpact of breast cancer chemotherapy on ovarian damage and recovery.
Goldfarb S, Bedoschi G, Turan V, Crown A, Abdo N, Dickler M, Oktay K. Impact of breast cancer chemotherapy on ovarian damage and recovery. Journal Of Clinical Oncology 2020, 38: e24059-e24059. DOI: 10.1200/jco.2020.38.15_suppl.e24059.Peer-Reviewed Original ResearchAMH recoveryBreast cancerBaseline AMHOvarian reserveNon-metastatic breast cancerBaseline AMH levelsTime of diagnosisBreast cancer patientsBreast cancer chemotherapyImpact of chemoImportant predictorCancer ptsChemo groupGonadotoxic chemoChemotherapy regimenOvarian damageSerum AMHAMH levelsStudy entryTamoxifen treatmentFertility preservationLow AMHProspective studyCancer patientsFuture fertility
2019
Ovarian Stimulation in Women with Breast Cancer
Turan V, Oktay K. Ovarian Stimulation in Women with Breast Cancer. 2019, 105-115. DOI: 10.1007/978-3-030-24086-8_10.Peer-Reviewed Original ResearchFertility preservation optionsOvarian stimulationBreast cancerPreservation optionsEffective fertility preservation optionsEstrogen-sensitive malignanciesReproductive-aged womenCommon cancer typesCytotoxic chemotherapyGonadal failureAged womenOocyte cryopreservationNumber of womenCancer typesCancerWomenStimulationTreatmentHigh levelsChemotherapyPatientsMalignancyOptionsRadiotherapyEstradiol
2016
Embryo Cryopreservation in Breast Cancer Patients
Bedoschi G, Oktay K. Embryo Cryopreservation in Breast Cancer Patients. 2016, 39-52. DOI: 10.1007/978-4-431-55963-4_3.Peer-Reviewed Original ResearchBreast cancer patientsCancer patientsFertility preservationEmbryo cryopreservationAdjuvant systemic chemotherapyFertility preservation techniquesOvarian stimulation protocolsBreast cancer casesOvarian stimulationSystemic chemotherapyOvarian reserveIncident casesAromatase inhibitorsBreast cancerCancer casesStimulation protocolPatientsDonor semenCommon typeWomenFuture reproductive potentialCancerPreservation techniquesAttractive strategySpecial consideration
2015
Comparison of random start controlled ovarian stimulation with standard start in letrozole gonadotropin cycles for fertility preservation in women with breast cancer
Bedoschi G, Turan V, Emirdar V, Sonmezer M, Oktay K. Comparison of random start controlled ovarian stimulation with standard start in letrozole gonadotropin cycles for fertility preservation in women with breast cancer. Fertility And Sterility 2015, 104: e267. DOI: 10.1016/j.fertnstert.2015.07.838.Peer-Reviewed Original ResearchLong-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor treatment in women with breast cancer.
Oktay K, Turan V, Kim J. Long-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor treatment in women with breast cancer. Journal Of Clinical Oncology 2015, 33: 9521-9521. DOI: 10.1200/jco.2015.33.15_suppl.9521.Peer-Reviewed Original Research
2014
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropin in patients with breast cancer: a prospective controlled study with subgroup analysis
Kim J, Turan V, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropin in patients with breast cancer: a prospective controlled study with subgroup analysis. Fertility And Sterility 2014, 102: e32. DOI: 10.1016/j.fertnstert.2014.07.118.Peer-Reviewed Original Research
2013
The impact of long-term tamoxifen treatment on ovarian reserve markers in women with breast cancer: a prospective-longitudinal study
Oktay K, Bedoschi G, Dickler M, Goldfarb S, Turan V, Moy F. The impact of long-term tamoxifen treatment on ovarian reserve markers in women with breast cancer: a prospective-longitudinal study. Fertility And Sterility 2013, 100: s64. DOI: 10.1016/j.fertnstert.2013.07.1879.Peer-Reviewed Original ResearchSafety and feasibility of performing two consecutive Letrozole-FSH stimulation cycles for fertility preservation in women with breast cancer
Bedoschi G, Turan V, Oktay K. Safety and feasibility of performing two consecutive Letrozole-FSH stimulation cycles for fertility preservation in women with breast cancer. Fertility And Sterility 2013, 100: s65. DOI: 10.1016/j.fertnstert.2013.07.1883.Peer-Reviewed Original ResearchFertility preservation in young breast cancer patients: addressing individual patient needs
Rodriguez-Wallberg K, Oktay K. Fertility preservation in young breast cancer patients: addressing individual patient needs. Breast Cancer Management 2013, 2: 135-147. DOI: 10.2217/bmt.12.68.Peer-Reviewed Original ResearchBreast cancer patientsFertility preservationCancer patientsAromatase inhibitorsYoung breast cancer patientsOvarian cortical tissueNumber of oocytesStandard stimulation protocolIndividual patient needsReports of childrenFemale patientsEstradiol levelsMenstrual cycleOocyte freezingBreast cancerPsychosocial distressStimulation protocolNormal rangePatient needsPatientsCortical tissueYoung womenImmature oocytesTamoxifenInfertility
2011
A multicenter analysis of the predictors of fertility preservation in women with breast cancer: Role of neoadjuvant chemotherapy.
Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau J. A multicenter analysis of the predictors of fertility preservation in women with breast cancer: Role of neoadjuvant chemotherapy. Journal Of Clinical Oncology 2011, 29: 9118-9118. DOI: 10.1200/jco.2011.29.15_suppl.9118.Peer-Reviewed Original ResearchInfertility as a risk factor of ovarian and breast cancer
Kim J, Oktay K. Infertility as a risk factor of ovarian and breast cancer. Expert Review Of Obstetrics & Gynecology 2011, 6: 153-161. DOI: 10.1586/eog.11.2.Peer-Reviewed Original Research
2010
Access to fertility preservation and post-chemotherapy assisted reproduction in women with breast cancer
Lee S, Heytens E, Ozkavukcu S, Rosen A, Moy F, Oktay K. Access to fertility preservation and post-chemotherapy assisted reproduction in women with breast cancer. Fertility And Sterility 2010, 94: s66. DOI: 10.1016/j.fertnstert.2010.07.258.Peer-Reviewed Original ResearchDoes higher starting dose of FSH stimulation improve fertility preservation cycle outcomes in women with breast cancer?
Oktay K, Lee S. Does higher starting dose of FSH stimulation improve fertility preservation cycle outcomes in women with breast cancer? Fertility And Sterility 2010, 94: s160. DOI: 10.1016/j.fertnstert.2010.07.637.Peer-Reviewed Original Research